ArticleSisli Etfal Hastanesi tip bulteni2026
Determinant Factors for The Efficacy of Botulinum Toxin Injections on Lower Limb Function in Cerebral Palsy: Two Year Follow-up Study.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study evaluated the factors predicting the effect of long-term intramuscular botulinum toxin-A (BTX-A) treatment on motor and gait functions in children with spastic cerebral palsy (CP). Methods: Two hundred children diagnosed with CP were treated with BTX-A, with particular attention given to the lower limbs. The children were followed up for over two years. The severity of spasticity was evaluated using the Modified Ashworth Scale. The Gross Motor Function Classification System (GMFCS) and Observational Gait Scale (OGS) were used to assess changes in motor and gait function scores. Outcomes at the end of two years were compared with baseline values. Results: After two years, the severity of spasticity and the GMFCS and OGS scores improved with BTX-A treatment. The most important factors predicting improvement in motor scores after treatment were young age, high baseline OGS scores, independent walking, baseline GMFCS scores, and hemiplegia. The determinant factors for improvement in gait scores were the number of injections and a high baseline GMFCS level. Conclusion: The predictors of the efficacy of BTX-A treatment on gait and motor function were young age, independent ambulatory status, gross motor function level, high baseline gait scores, hemiplegic type of CP, and multiple BTX-A injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.